Trending Topics

Trending Topics

108 Trending Topics found

ASTRO News: Adding Immunotherapy to Chemoradiation Decreases Local and Distant Recurrence of NSCLC

A new analysis of survival data for the randomized, phase III PACIFIC trial finds adding the immunotherapy cancer drug durvalumab to radiation and chemotherapy significantly decreased the recurrence of lung cancer both in the chest area and in distant sites outside the chest. The updated PACIFIC trial data will be presented at the 61st Annual Meeting of the American Society for Radiation Oncology (ASTRO), by Andreas Rimner, MD, radiation oncologist, Memorial Sloan Kettering Cancer Center.

  • Monday, September 16, 2019

Promising Data for RET Fusion-Positive Lung Cancer Patients with Targeted Therapy, Selpercatinib, Presented at the 2019 World Congress on Lung Cancer

Selpercatinib (also known as LOXO-292) is a highly selective RET inhibitor with activity against diverse RET fusions, activating RET mutations and brain metastasis. Phase 1/2 data from the LIBRETTO-001 trial presented at the IASLC 2019 World Conference on Lung Cancer demonstrates selpercatinib’s marked antitumor activity in RET fusion-position non-small cell lung cancer (NSCLC) patients. These findings, presented by Alexander Drilon, MD, principal investigator and Research Director of Early Drug Development at Memorial Sloan Kettering Cancer Center, will form the basis of an US Food and Drug Administration new drug application submission.

  • Monday, September 9, 2019

New Study Examines Wilms’ Tumor Relapse and May Give Clues to about Which Other Childhood Cancers Could Relapse

Today, researchers from MSK Kids at Memorial Sloan Kettering Cancer Center (MSK) published results that examine elevated levels of a protein called prohibitin in the urine and tumors of children with Wilms’ tumors. Their findings could help doctors identify children who are at risk for disease recurrence and precisely tailor treatment to overcome drug resistance.

  • Thursday, August 8, 2019

Memorial Sloan Kettering Among the Top “Best Hospitals” for Cancer Care and Ranked First in Gynecology by U.S News & World Report

Memorial Sloan Kettering Cancer Center (MSK) has been ranked as the number two hospital for cancer care in the nation, according to U.S. News & World Report in its annual listing of Best Hospitals. Since the inception of the rankings 30 years ago, MSK has held either the first or second spot each year for cancer care. MSK was also ranked first in gynecology.

  • Tuesday, July 30, 2019

Cracking a Code: Landmark Prospective Study Helps Researchers Better Understand Which MGUS Patients Will Progress to a Multiple Myeloma Diagnosis

Memorial Sloan Kettering Cancer Center (MSK) researchers published new results that found that individuals with low-risk or intermediate-risk myeloma precursor disease known as monoclonal gammopathy of undetermined significance (MGUS) can convert to high-risk MGUS and progress to multiple myeloma within a five-year window. This research clinically supports recommendations for annual blood tests for all individuals diagnosed with MGUS along with re-assessments of a patient’s clinical-risk status. Their research was published today online in JAMA Oncology.

  • Thursday, July 18, 2019

Surviving with Pride: Obstacles and Opportunities for LGBTQ+ Cancer Survivors

Today is the fourth anniversary of same-sex marriage being legalized in the United States. Today also marks the start of WorldPride, which celebrates the progress made toward LGBTQ+ equality while underscoring changes still needed.

  • Thursday, June 27, 2019

MSK-ACCESS Receives New York State Approval for New Molecular Assay

Memorial Sloan Kettering Cancer Center (MSK) today announced that the New York State Department of Health has issued approval for a new molecular assay, Analysis of Circulating cfDNA to Evaluate Somatic Status (MSK-ACCESS).  MSK-ACCESS was developed within the Marie-Josee and Henry R. Kravis Center for Molecular Oncology (CMO) and the test has been clinically validated and implemented by members of MSK’s Molecular Diagnostics Service.

  • Tuesday, June 11, 2019

MSK Research and Experts at the 2019 ASCO Annual Meeting: Caring for Every Patient, Learning from Every Patient

More than 30,000 oncology professionals from around the world will gather in Chicago from May 31 to June 4 for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. For more information and to set up interviews, email Follow the meeting live on Twitter using the hashtag #ASCO19 and follow MSK on Twitter at @sloan_kettering.

  • Wednesday, May 29, 2019

World-Renowned Molecular Biologist Maria Jasin Wins the Shaw Prize in Life Science and Medicine

Maria Jasin, PhD, a molecular biologist at the Sloan Kettering Institute, was named a recipient of the Shaw Prize in Life Science and Medicine. Dr. Jasin was recognized for her contributions to research showing that localized double-strand breaks in DNA stimulate recombination in mammalian cells.

  • Tuesday, May 21, 2019

High-Impact Science and Clinical Trial Results from MSK Experts Highlighted at the AACR 2019 Annual Meeting

Thousands of oncology experts from around the world will gather in Atlanta from March 29 – April 3 for the American Association for Cancer Research (AACR) Annual Meeting 2019. Memorial Sloan Kettering experts are involved in notable research presented at the meeting and are available to comment on topics including immunotherapy, precision medicine and targeted treatments, genomics, cancer interception and prevention, clinical trial design, cancer health disparities, and more. For more information and to set up interviews or access photos and video, contact and

  • Thursday, March 28, 2019